Article
The Design for a Phase II, Randomized, Multicenter Study of CtDNA-Guided Treatment With Furmonertinib Combined Therapy or Furmonertinib Alone for Untreated Advanced EGFR Mutant Non-small-cell Lung Cancer Patients: The FOCUS-C Study.
Clinical lung cancer - 1 Nov 2024
Zhang Yaxiong, Chen Zihong, Chen Gang, Huang Yan, Yang Yunpeng, Fang Wenfeng, Zhang Li
Abstract excerpt
BACKGROUND: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have significant antitumor activity to advanced non-small-cell lung cancer (NSCLC) patients with classic EGFR mutations. However, EGFR-TKI monotherapy shows poor efficacy in patients whose circulating tumor cell DNA (ctDNA) of EGFR mutations cannot be rapidly cleared. MATERIALS AND METHODS: As a third-generation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.